Clik here to view.
At Third Arc Bio, former J&J leaders raise $165M to test oncology, autoimmune...
After more than a decade steering Johnson & Johnson’s oncology drug R&D, Peter Lebowitz is ready for his next challenge: shepherding the “third arc” of biologics development. “The first one was...
View ArticleClik here to view.
Bob Langer, Flagship's Stephen Berenson to depart Moderna's board as Carlyle...
Robert Langer is leaving the board of Moderna, the biotech he co-founded and that soared to unexpected heights during the Covid-19 pandemic because of its pioneering mRNA vaccine. David Rubenstein The...
View ArticleDevelopers of next obesity drugs see an opening in shortages, as field...
Ever since the weight loss drug craze created near-unprecedented demand, the first two companies to market have been doing everything they can to meet it by investing in old facilities, building new...
View ArticleTelix's $397M convertible bond offering; Scynexis records a $10M milestone
Plus, news about Windtree Therapeutics, MEI Pharma and ViiV: Telix raises $397M in convertible bond offering: The radiopharma biotech plans to use the funds to advance key programs in its pipeline,...
View ArticleNeurology startup from OrbiMed collab nabs $65M in Series A
Brenig Therapeutics closed a $65 million Series A on Tuesday morning, getting backing from big-name investors such as New Enterprise Associates and OrbiMed. The company will focus on neurology, with...
View ArticleCellectar to seek approval for radioactive iodine-based therapy in rare blood...
Cellectar Biosciences reported Tuesday that 80% of patients with a rare blood cancer evaluated in a pivotal study responded to the company’s iodine-based treatment, and it plans to apply to the FDA for...
View ArticlePfizer lifts curtain on $740M+ extension at API manufacturing site in Singapore
To further entrench its roots in Singapore, Pfizer has opened the doors to a facility extension at a local plant to boost API production for its oncology, pain and antibiotic franchises. The US...
View ArticleUpdated: Merck, without sharing details, says RSV antibody successfully...
Merck’s monoclonal antibody to protect infants from RSV hit its goals in a Phase 2b/3 trial, putting the US drugmaker a step closer to competing against Sanofi and AstraZeneca’s rival product. The...
View ArticleIndian manufacturer Brassica hit with warning letter after employees faked...
The FDA has issued Indian CDMO Brassica Pharma a warning letter after inspectors found employees routinely falsified data records. The regulator inspected Brassica’s facility in the town of Tarapur,...
View ArticleWhat's changed about rare disease medicine
(This is our latest issue of Post-Hoc, a dispatch of analysis and perspectives from the Endpoints newsroom. To get it directly in your inbox, you can modify your subscription preferences here in the...
View ArticleAbbVie files lawsuit in Missouri federal court over 340B contract pharmacies
AbbVie is bringing its legal fight over 340B restrictions to another state. The Chicago pharma giant on Monday filed suit in Missouri over a new state law that would keep drugmakers from imposing...
View ArticleFDA asks adcomm if AstraZeneca needs another study on Imfinzi before and...
The FDA outlined concerns of overtreatment in AstraZeneca’s clinical trial of its immune checkpoint drug before and after lung cancer surgery ahead of a public panel with outside experts on Thursday....
View ArticlePBM executives dodge grilling in House committee hearing
Chief executives from the three largest pharmacy benefit managers (PBMs) steered around most of the difficult questions at a congressional hearing, repeatedly blaming rising prescription drug prices on...
View ArticleClik here to view.
AstraZeneca and Pinetree sign preclinical EGFR drug deal
With $45 million in upfront and near-term payments, AstraZeneca is working to expand its EGFR pipeline through a deal with Pinetree Therapeutics for a preclinical protein degrader. Pinetree is eligible...
View ArticleRA Capital invests $35M in UK cancer biotech CellCentric
UK biotech CellCentric is getting a $35 million boost from RA Capital to further develop its multiple myeloma pill. The capital infusion will help CellCentric get its drug, inobrodib, through mid-stage...
View ArticleClik here to view.
Activist investor calls for board shakeup at Assertio, threatens proxy contest
An investor in Chicago-area pharmaceutical company Assertio Holdings is calling on the small drugmaker to shake up its board and has threatened a proxy battle if changes aren’t made. Buxton Helmsley...
View ArticleWith new mission in psychiatry, Autobahn raises $100M to help back Phase 2 work
Autobahn Therapeutics’ journey through the clinic has been anything but speedy. The ARCH-backed startup launched out of stealth more than four years ago in June 2020, armed with $76 million to try to...
View ArticleHangzhou Jiuyuan files for Hong Kong IPO
A Chinese company with plans to commercialize biosimilar GLP-1 drugs is seeking to go public in Hong Kong, in a test of investor enthusiasm amid a prolonged slowdown. The Wednesday filing marks...
View ArticleClik here to view.
Sage's essential tremor drug fails in another blow to pipeline, Biogen...
Sage and its partner Biogen said their experimental oral medicine failed a Phase 2 test in essential tremor and they will stop development in the nervous system disorder, which leads to involuntary...
View ArticlePfizer touts Phase 3 gene therapy data in hemophilia A, but now it needs to...
Can Pfizer do what BioMarin couldn’t in hemophilia A? Pfizer announced Wednesday that its gene therapy for hemophilia A met the primary objective in a key clinical trial, and the company plans to bring...
View Article